Literature DB >> 16207517

Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol.

Yusuke Sakai1, Shin-Ichi Yasueda, Akira Ohtori.   

Abstract

Latanoprost in water is not stable against heat stress due to hydrolysis of the isopropyl ester in the latanoprost molecule. Therefore, the storage condition of latanoprost ophthalmic solution, Xalatan brand, was in a low temperature (2-8 degrees C). We formulated a favorable ophthalmic lipid emulsion of latanoprost using polyvinyl alcohol as emulsifier which showed a good heat stability. The assays of the latanoprost ophthalmic lipid emulsions adjusted to pH 5.0, 6.0 and 7.0 were 100.4%, 100.7% and 99.2% after storage for 4 weeks at 60 degrees C, respectively. The possibility of room temperature storage for the latanoprost ophthalmic lipid emulsion was demonstrated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16207517     DOI: 10.1016/j.ijpharm.2005.08.017

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  4 in total

1.  Comparison of hydroxylated print additives on antibody microarray performance.

Authors:  Peng Wu; David W Grainger
Journal:  J Proteome Res       Date:  2006-11       Impact factor: 4.466

2.  Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye.

Authors:  Jayaganesh V Natarajan; Sujay Chattopadhyay; Marcus Ang; Anastasia Darwitan; Selin Foo; Ma Zhen; Magdalene Koo; Tina T Wong; Subbu S Venkatraman
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

3.  Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye.

Authors:  Jayaganesh V Natarajan; Marcus Ang; Anastasia Darwitan; Sujay Chattopadhyay; Tina T Wong; Subbu S Venkatraman
Journal:  Int J Nanomedicine       Date:  2012-01-05

4.  Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study.

Authors:  Mauricio D Paolera; Niro Kasahara; Cristiano C Umbelino; John G Walt
Journal:  BMC Ophthalmol       Date:  2008-06-11       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.